NxStage Medical Moves To Break-Even in Q3, Tops Street Views on Earnings, Revenues

NxStage Medical (NXTM), maker of home hemodialysis systems, Thursday reported earnings and revenues above Street views and boosted full-year guidance.

NxStage reported a break-even EPS for Q3, better than the $0.04 loss expected by the Street as compiled by Capital IQ, and also better than the $0.03 loss reported a year earlier.

The company reported Q3 revenues of $92.0 million, above the Street view of $89.7 million, and also above the $86.5 million reported a year earlier.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

For full-year of 2016, NxStage said it “expects revenue to be at the high end of its previously increased guidance range of $360 to $365 million, and a net loss in a range of $4 to $5 million versus its previously revised guidance for a loss at the better end of a range of $7 to $12 million. For the fourth quarter of 2016, the company expects revenue to be approximately $92 million with a net loss in the range of $1 to $2 million.”

NxStage slated a 9:00 am ET conference call.